Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights

Crescent Biopharma reported Q1 2026 revenue of $1.0 million versus no revenue in the prior year, driven by the $20 million upfront payment from Kelun-Biotech for the CR-001 license agreement. The company ended the quarter with $189.2 million in cash, sufficient to fund operations into 2028, while net loss widened to $23.3 million from $15.1 million year-over-year due to increased R&D and G&A spending. Pipeline progress remains on track, with the ASCEND Phase 1/2 trial of lead asset CR-001 ongoing and the first ADC combination trial expected to begin in the second half of 2026.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.